康莱特注射液治疗晚期非小细胞肺癌的临床疗效观察  

Clinical efficacy of kanglaite injection in treatment of advanced non-small-cell lung cancer

作　　者：张圣林[1] 刘春丽[1] 梁君伟[1] 王淑萍[1] 郝玉静[1] 李青山[1] 

机构地区：[1]承德医学院附属医院放化疗科,河北承德067000

出　　处：《中国热带医学》2012年第5期607-608,614,共3页China Tropical Medicine

摘　　要：目的观察康莱特注射液治疗晚期非小细胞肺癌的临床疗效。方法将60例原发性肺癌随机分为两组:观察组和对照组均为30例。观察组采用康莱特注射液静脉点滴治疗;对照组采用一线化疗方案静脉点滴全身化疗。观察临床近期疗效(包括有效率及稳定率)、Karnofsky评分、体重变化、不良反应。结果上述观察的各项指标,除近期疗效有效率相近,两组比较差异无统计学意义(χ2=0.325,P>0.05),观察组的karnofsky评分、体重变化、不良反应等情况均明显优于对照组,两组比较差异有统计学意义(χ2=6.550,P<0.01)。结论康莱特注射液治疗晚期非小细胞肺癌较应用一线化疗方案化疗能明显改善症状,提高生存质量,使患者体重明显增加,而且没有明显毒副反应。Objective To observe clinical efficacy of Kanglaite injection in treatment of advanced non-small-cell lung cancer.Methods 60 primary lung cancer cases were randomly divided into two groups： the observation group（30 cases）and the control group（30cases）.The observation group was treated with Kanglaite injection,control group with first-line chemotherapy.The comparison was done in the response rate,stability,Karnofsky score,weight change and adverse reaction.Results Karnofsky score,weight change and adverse reactions in the observation group were significantly improved compared to the control group（P〈0.05）except the response rate.Conclusion Kanglaite injection in treatment of advanced non small cell lung cancer can improve significantly the symptoms,life quality,body mass,without obvious toxic and adverse reaction.

关 键 词：康莱特注射液 晚期肺癌 化疗 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]